期刊
FEBS LETTERS
卷 583, 期 14, 页码 2419-2424出版社
WILEY
DOI: 10.1016/j.febslet.2009.06.042
关键词
Tau; Alpha-synuclein; Inhibitor; Alzheimer; ALS; FTLD
资金
- Ministry of Education, Culture, Sports, Science and Technology [20023038]
- Ministry of Health, Labor and Welfare of Japan
- Russian Foundation for Basic Research [09-04-01412-a]
- MRC [MC_U105184291] Funding Source: UKRI
- Medical Research Council [MC_U105184291] Funding Source: researchfish
- Grants-in-Aid for Scientific Research [20023038, 21591536] Funding Source: KAKEN
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) are major neurodegenerative diseases with TDP-43 pathology. Here we investigated the effects of methylene blue (MB) and dimebon, two compounds that have been reported to be beneficial in phase II clinical trials of Alzheimer's disease (AD), on the formation of TDP-43 aggregates in SH-SY5Y cells. Following treatment with 0.05 mu M MB or 5 mu M dimebon, the number of TDP-43 aggregates was reduced by 50% and 45%, respectively. The combined use of MB and dimebon resulted in a 80% reduction in the number. These findings were confirmed by immunoblot analysis. The results indicate that MB and dimebon may be useful for the treatment of ALS, FTLD-U and other TDP-43 proteinopathies. (C) 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据